Heron Therapeuti
USUSDHeron Therapeuti (LSE:0J4V) — Biotechnology: Pharmaceutical Preparations. Numărul de burse pe care se tranzacționează acțiunile companiei: 2. Pe această pagină — preț și grafic, dividende, principalii deținători și istoricul numărului de acțiuni.
Despre Companie
- Site Web
- herontx.com
- Relații cu Investitorii
- ir.herontx.com/
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sediu Central
- SAN DIEGO, United States
- Director General
- Craig Alexander Collard
- Angajați
- 128
- Listată din
- 29.01.2018 (LSE:0J4V)
- Acțiuni în Circulație
- 189.85 mil. la 2026-08-05
- Free Float
- 146.52 mil.
- Capitalizare de Piață
- 77.1 mil. USD
- Insideri
- 0.98%
- Investitori Instituționali
- 70.98%
- Industrie (SIC)
- Pharmaceutical Preparations
- P/E
- pierdere
- FCF
- −12.1 mil. USD
- Datorie
- 64.0 mii USDnumerar net
- Câștiguri și FCF — pentru cele 12 luni până la 30.06.2026 (cel mai recent raport al companiei).
- NAV
Descriere
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Cei Mai Mari Acționari
| Deținător | Participație | Acțiuni | Data Raportului |
|---|---|---|---|
| Rubric Capital Managemen… | 15.83% | 30.05 mil. | 2026-06-30 |
| Clearline Capital, LP | 6% | 11.38 mil. | 2026-06-30 |
| Blackrock Inc. | 5.56% | 10.55 mil. | 2026-06-30 |
| MORGAN ADAM (Director) | ≈4.68% | 8.88 mil. | 2026-01-30 |
| Velan Capital Investment… | 4.61% | 8.75 mil. | 2026-06-30 |
| Vanguard Capital Managem… | 4.1% | 7.78 mil. | 2026-06-30 |
| Tejara Capital Ltd | 3.43% | 6.51 mil. | 2026-06-30 |
| Tang Capital Management,… | 3.29% | 6.25 mil. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.88% | 5.47 mil. | 2026-06-30 |
| Geode Capital Management… | 2.25% | 4.27 mil. | 2026-06-30 |
| Millennium Management Ll… | 2.14% | 4.07 mil. | 2026-06-30 |
| JW Asset Management, LLC | 1.98% | 3.75 mil. | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.91% | 3.63 mil. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.09% | 2.06 mil. | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.86% | 1.63 mil. | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.72% | 1.37 mil. | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.46% | 869 904 | 2026-05-31 |
| COLLARD CRAIG ALEXANDER… | ≈0.45% | 856 492 | 2026-07-31 |
| VANGUARD SCOTTSDALE FUND… | 0.41% | 783 992 | 2026-05-31 |
| Fidelity Concord Street… | 0.33% | 635 712 | 2026-07-31 |
| iShares Trust-iShares Mi… | 0.28% | 533 800 | 2026-08-31 |
| iShares Trust-iShares Ru… | 0.27% | 504 982 | 2026-08-31 |
| DUARTE IRA (Chief Financ… | ≈0.15% | 281 899 | 2026-07-31 |
| FORBES WILLIAM P (Office… | ≈0.13% | 241 173 | 2026-07-31 |
| HENSLEY MARK EARL (Chief… | ≈0.09% | 170 901 | 2026-08-06 |
| RODRIGUEZ SUSAN (Directo… | ≈0.05% | 87 180 | 2025-01-31 |
| CUSACK THOMAS J (Directo… | ≈0.03% | 53 960 | 2026-01-30 |
| JOHNSON CRAIG A (Directo… | ≈0.03% | 53 960 | 2026-01-30 |
| KASETA MICHAEL (Director… | ≈0.03% | 53 960 | 2026-01-30 |
| RUBRIC CAPITAL MANAGEMEN… | — | — | 2025-10-15 |
Conectează-te cu Google